As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.

French healthcare company Ipsen agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, helping to boost Ipsen’s portfolio of products treating rare diseases.